RecruitingNCT05765500Updated Jul 30, 2026

RecoverPC: Relugolix vs GnRH Agonist in Quality of Life

A Phase 2 interventional study of Relugolix and Leuprolide in Prostate Cancer and Prostatic Neoplasms, sponsored by Dana-Farber Cancer Institute. Recruiting at 3 sites in United States. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-30.

Sponsored by Dana-Farber Cancer Institute · Phase 2, Interventional, and Treatment

From the registry’s dates

Started Feb 2024; still recruiting 2 years 7 months later.

Phase: Phase 2
Study type: Interventional
Enrollment: 110
Allocation: Randomized
Ages: 18 Years and older
Sex: Male

Study summary

This study is testing the way that approved androgen deprivation therapy treatments, Leuprolide and Relugolix, for prostate cancer affect quality of life, blood levels, cholesterol, and blood sugar. The drugs are already standard treatment for people with prostate cancer, and the drugs will be used as described in their label.

The names of the study drugs involved in this study are:

Leuprolide (type of ADT)
Relugolix (type of ADT)

Read the detailed description

This is a phase 2 clinical trial comparing patient-reported Quality of Life (QOL) among men with localized or biochemically recurrent prostate cancer treated with relugolix versus leuprolide depot therapy.

Participants will be randomized into one of the study groups leuprolide versus relugolix. Randomization means that a participant is put into a study group by chance.

The U.S. Food and Drug Administration (FDA) has approved leuprolide and relugolix as treatment options for prostate cancer.

The research study procedures include screening for eligibility and study treatment including evaluations and follow up visits, ECGs, and blood tests.

Participation in this research study is expected to last 12 months.

It is expected about 110 people will take part in this research study.

The Prostate Cancer Foundation and Pfizer are supporting this research study by providing funding. Myovant is supporting this study by providing the drug, Relugolix.

Conditions studied

Prostate Cancer
Prostatic Neoplasms

Browse trials for

Prostatic Neoplasms 6,370

Keywords

Prostate Cancer
Prostate Neoplasms

In context

Prostatic Neoplasms

6,370 studies on the registry are indexed under Prostatic Neoplasms; 1,400 are open to participants now.

This study's planned enrollment of 110 is above the median of 58 across 4,822 interventional studies indexed under Prostatic Neoplasms.

Browse Prostatic Neoplasms studies →

Lead sponsor

Dana-Farber Cancer Institute is the lead sponsor of 813 studies on the registry; 124 are open to participants now.

Of its 113 completed or terminated interventional studies of FDA-regulated products, 77 (68%) have results posted.

Counted across the registry records on this site, refreshed daily.

Who can participate

Ages eligible: 18 Years and older
Sexes eligible: Male
Accepts healthy volunteers: No

Inclusion criteria

Participants must have a histologic diagnosis of prostate adenocarcinoma.
Participants must be eligible for treatment with 6 months of ADT with leuprolide depot or relugolix without additional systemic therapies other than first generation androgen receptor antagonists (eg. bicalutamide, nilutamide, flutamide).
Participants cannot have received prior GnRH agonist or antagonist therapy.
Patients must have testosterone level > 200 ng/mL prior to initiation of ADT.
Age ≥18 years.
ECOG performance status ≤2 (Karnofsky ≥60%, see Appendix A).
Life expectancy of greater than 12 months
Participants must have adequate organ and marrow function as defined below:
- leukocytes ≥3,000/mcL
- absolute neutrophil count ≥1,500/mcL
- platelets ≥100,000/mcL
- total bilirubin ≤ institutional upper limit of normal (ULN) unless known or suspected Gilbert syndrome
- AST(SGOT)/ALT(SGPT) ≤3 × institutional ULN
- creatinine ≤ institutional ULN OR
- glomerular filtration rate (GFR) ≥50 mL/min/1.73 m2 unless data exists supporting safe use at lower kidney function values, no lower than 30 mL/min/1.73 m2 (see Appendix B).
Human immunodeficiency virus (HIV)-infected participants on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial.
For participants with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated.
Participants with a history of hepatitis C virus (HCV) infection must have been treated and cured. For participants with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load.
Participants with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial.
Participants with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, participants should be class 2B or better.
The effects of relugolix and leuprolide on the developing human fetus are unknown. For this reason and because GnRH agents are known to be teratogenic, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 4 months after completion of relugolix or leuprolide depot administration.
Ability to understand and the willingness to sign a written informed consent document.

Exclusion criteria

Exclusion Criteria:

History of major adverse cardiac event, including myocardial infarction, new congestive heart failure (CHF) or CHF exacerbation, or stroke, within the past 6 months.
Participants who have prior or planned concurrent treatment with second generation AR targeted therapies (such as abiraterone, enzalutamide, darolutamide, apalutamide).
Participants who are receiving any other investigational agents.
Patients with brain metastases will be excluded from the study as intermittent hormonal therapy is not standard of care treatment for this population.
History of allergic reactions attributed to compounds of similar chemical or biologic composition to leuprolide depot or relugolix.
Participants with uncontrolled intercurrent illness.
Participant is unable to swallow pills.

Study design

Phase: Phase 2
Primary purpose: Treatment
Allocation: Randomized
Intervention model: Parallel assignment
Masking: Single (Participant)
Enrollment: 110 participants (estimated)

Study arms

Experimental
Arm A: Relugolix
55 participants will be randomized in a 1:1 fashion to Relugolix and stratified by intent to treat with radiation and will complete study procedures as outlined: * Surveys at baseline and at months 3, 6, 9, and 12. * Medication diary entries. * Cycles 1 - 6: --Days 1 - 28 of 28 day cycle: Predetermined dose of Relugolix. Participant will self-administer at home. * Follow up visits every 3 months for 12 months.
Drug: Relugolix
Active comparator
Arm B: Leuprolide
55 participants will be randomized in a 1:1 fashion to Leuprolide and stratified by intent to treat with radiation and will complete study procedures as outlined: * Surveys at baseline and at months 3, 6, 9, and 12. * Cycle 1 and Cycle 4: --Day 1 of 28 day cycle: Predetermined dose of Leuprolide. Injection will be administered in clinic. * Follow up visits every 3 months for 12 months.
Drug: Leuprolide

Interventions

DrugRelugolix
Gonadotropin-releasing hormone (GnRH) antagonist, oral tablet taken 1x daily.
Also known as: Orgovyx
DrugLeuprolide
Gonadotropin-releasing hormone (GnRH) antagonist, intramuscular injection 1x every 3 months.
Also known as: Leuprolide Depot

What researchers measure

Primary outcomes

9-month Quality of Life (QOL) Score
The QOL assessed using Functional Assessment of Cancer Therapy - Prostate (FACT-P) questionnaire, defined protocol section 11.1.1: The FACT-P (version 4) contains 39 Likert-type items distributed over 5 subscales: physical (7 items), social/family (7 items), emotional (6 items), and functional (7 items) well-being, and the additional concerns related to prostate cancer scale (12 items). The FACT-P total score is calculated by summing all these 5 subscales and ranges from 0 to 156.
Time frame: At 9 months

Secondary outcomes

12-month Quality of Life (QOL) Score
The QOL assessed using Functional Assessment of Cancer Therapy - Prostate (FACT-P) questionnaire, defined protocol section 11.1.1: The FACT-P (version 4) contains 39 Likert-type items distributed over 5 subscales: physical (7 items), social/family (7 items), emotional (6 items), and functional (7 items) well-being, and the additional concerns related to prostate cancer scale (12 items). The FACT-P total score is calculated by summing all these 5 subscales and ranges from 0 to 156.
Time frame: At 12 months
9-month Hot flash related daily interference scale (HFRDIS)
HFRDIS was Self-reported daily hot flash interference will be assessed with the Hot Flash-Related Daily Interference Scale, a valid and reliable measure used in prior prostate cancer studies. This scale assesses the impact of hot flashes on daily activities as well as overall quality of life. Total scores range from 0 - 100; higher scores indicate greater interference.
Time frame: At 9 months
9-month Insomnia Severity Index (ISI) Score
ISI Insomnia symptoms will be assessed using the ISI, which has been used in previous assessments of cancer patients, including men with prostate cancer. This questionnaire has 7 items asking about difficulties falling asleep, staying asleep, problems with waking too early and the satisfaction level with their current sleep pattern. Each item was rated on a scale from 0 to 4, where a higher score indicates a more severe insomnia.
Time frame: At 9 months
9-month Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-Fatigue) Score
Fatigue symptoms will be assessed with the FACIT-Fatigue survey, a valid and reliable instrument used in prostate cancer and other cancer studies, comprised of 13 items and rated on a 5 point Likert-type scale.
Time frame: At 9 months
9-month EPIC-26 Sexual Function Summary Score
Self-reported sexual function will be assessed using the sexual health section of the EPIC-26.
Time frame: At 9 months
12-month Hot flash related daily interference scale (HFRDIS)
HFRDIS was Self-reported daily hot flash interference will be assessed with the Hot Flash-Related Daily Interference Scale. This scale assesses the impact of hot flashes on daily activities as well as overall quality of life. Total scores range from 0 - 100; higher scores indicate greater interference.
Time frame: At 12 months

Study locations

2 of 3 sites recruiting

Brigham and Women's Hospital
Boston, Massachusetts 02215, United States
- Alicia Morgans, MD · Contact · aliciak_morgans@dfci.harvard.edu · 857-215-1605
Not yet recruiting
Dana-Farber Cancer Institute
Boston, Massachusetts 02215, United States
- Alicia Morgans, MD · Contact · aliciak_morgans@dfci.harvard.edu · 857-215-1605
Recruiting
Dana-Farber Cancer Institute at Foxborough
Foxborough, Massachusetts 02035, United States
- Daniel Roberts, MD · Contact · Daniel_Roberts@DFCI.HARVARD.EDU · 508-543-1700
Recruiting

References and documents

Individual participant data

Plan to share: Yes — The Dana-Farber / Harvard Cancer Center encourages and supports the responsible and ethical sharing of data from clinical trials. De-identified participant data from the final research dataset used in the published manuscript may only be shared under the terms of a Data Use Agreement. Requests may be directed to: \[contact information for Sponsor Investigator or designee\]. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.

Supporting information: Study protocol, Sap, Icf

No publications or documents are linked to this record.

Updates

Tracking since Sep 25, 2026

No changes since tracking began. The registry record was last updated on Jul 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗

Registry details

Key details

Study ID: NCT05765500
Lead sponsor: Dana-Farber Cancer Institute
Collaborators: Prostate Cancer Foundation, Pfizer, Sumitomo Pharma America, Inc.
Responsible party: Alicia Morgans (Principal Investigator, Dana-Farber Cancer Institute) — Principal investigator
First posted: Mar 13, 2023
Start date: Feb 12, 2024
Primary completion: Jul 1, 2027 (estimated)
Completion: Jan 1, 2028 (estimated)
Last update: Jul 30, 2026

Study contacts

Alicia Morgans, MD

Contact

aliciak_morgans@dfci.harvard.edu

857-215-1605

Alicia Morgans, MD

principal investigator · Dana-Farber Cancer Institute

Oversight

Data monitoring committee: Yes
FDA-regulated drug: Yes
FDA-regulated device: No

View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Prostatic Neoplasms→

Other studies from this sponsor

Dana-Farber Cancer Institute

Start the discussion